Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors

Clinical Lung Cancer

Volumn 13, Issue 4, 2012, Pages 267-279

  Bar, Jair ^a,b   Onn, Amir ^b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

EGFR; Irreversible tyrosine kinase inhibitors; NSCLC; Resistance; Reversible tyrosine kinase inhibitors

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; AFATINIB; CABOZANTINIB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CIXUTUMUMAB; CRIZOTINIB; DACOMITINIB; DALOTUZUMAB; DASATINIB; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; FICLATUZUMAB; FIGITUMUMAB; GANITUMAB; GEFITINIB; LINSITINIB; MEVINOLIN; PACLITAXEL; PLACEBO; RECOMBINANT ANTIBODY; RECOMBINANT ANTIBODY METMAB; RETASPIMYCIN; TIVANTINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACNE; ACUTE KIDNEY FAILURE; CANCER SURVIVAL; DEHYDRATION; DIARRHEA; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG WITHDRAWAL; DRY SKIN; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HEMOPTYSIS; HEPATORENAL SYNDROME; HUMAN; HYPERGLYCEMIA; IC 50; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LIVER FAILURE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; NONHUMAN; RECOMMENDED DRUG DOSE; REVIEW; THERAPY RESISTANCE; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84861627343     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.09.001     Document Type: Review

References (119)

1. ™. Non-Small Cell Lung Cancer. V.3.2011 http://www.nccn.org/professionals/physician-gls/PDF/nscl.pdf Accessed: May 21, 2011
2. D.J. Raz, B. He, R. Rosell Bronchioloalveolar carcinoma: a review Clin Lung Cancer 7 2006 313 322 (Pubitemid 43950978)
3. Surveillance Epidemiology and End Results, National Cancer Institute SEER Stat Fact Sheets: Lung and Bronchus http://seer.cancer.gov/statfacts/html/ lungb.html 2010 Accessed: April 30, 2010
4. AstraZeneca IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe http://www.astrazeneca.com/ Media/Press-releases/Article/20090701 - IRESSA-Gefitinib-Receives-Marketing- Authorisation-f Accessed: April 8, 2010
5. Roche's Tarceva gains positive CHMP opinion for first-line use in genetically distinct type of lung cancer http://www.roche.com/media/media- releases/med-cor-2011-07-22.htm Accessed: August 4, 2011
6. W.J. Gullick, J. Downward, P.J. Parker The structure and function of the epidermal growth factor receptor studied by using antisynthetic peptide antibodies Proc R Soc Lond B Biol Sci 226 1985 127 134 (Pubitemid 16192497)
7. T. Yamamoto, S. Ikawa, T. Akiyama Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor Nature 319 1986 230 234 (Pubitemid 16128786)
8. M.H. Kraus, W. Issing, T. Miki Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors Proc Natl Acad Sci U S A 86 1989 9193 9197 (Pubitemid 20010391)
9. G.D. Plowman, J.M. Culouscou, G.S. Whitney Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family Proc Natl Acad Sci U S A 90 1993 1746 1750 (Pubitemid 23069933)
10. L.A. Bazley, W.J. Gullick The epidermal growth factor receptor family Endocr Relat Cancer 12 suppl 1 2005 S17 S27
11. M.A. Olayioye, R.M. Neve, H.A. Lane The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J 19 2000 3159 3167 (Pubitemid 30428195)
12. M.K. Nicholas, R.V. Lukas, N.F. Jafri Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas Clin Cancer Res 12 2006 7261 7270 (Pubitemid 46095397)
13. F. Ciardiello, G. Tortora EGFR antagonists in cancer treatment N Engl J Med 358 2008 1160 1174
14. N.V. Sergina, M. Rausch, D. Wang Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 Nature 445 2007 437 441 (Pubitemid 46160912)
15. S.V. Sharma, D.W. Bell, J. Settleman Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 2007 169 181
16. M. Fukuoka, S. Yano, G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 2003 2237 2246 (Pubitemid 46621858)
17. M.G. Kris, R.B. Natale, R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2003 2149 2158 (Pubitemid 37432975)
18. F.A. Shepherd, P.J. Rodrigues, T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
19. A.E. Wakeling, S.P. Guy, J.R. Woodburn ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy Cancer Res 62 2002 5749 5754 (Pubitemid 35204731)
20. J.D. Moyer, E.G. Barbacci, K.K. Iwata Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res 57 1997 4838 4848 (Pubitemid 27468992)
21. N. Thatcher, A. Chang, P. Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537 (Pubitemid 41540110)
22. ® (gefitinib tablets) [package insert] 2005 AstraZeneca Pharmaceuticals LP Wilmington, DE
23. M. Maemondo, A. Inoue, K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
24. T. Mitsudomi, S. Morita, Y. Yatabe Gefitinib vs. cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
25. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer V.2.2010 http://www.nccn.org/ professionals/physician-gls/PDF/nscl.pdf Accessed: April 8, 2010
26. Erlotinib (Tarceva) for advanced non-small cell lung cancer Med Lett Drugs Ther 47 2005 25 26
27. FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer April 16, 2010 Genentech http://www.gene.com/gene/news/press- releases/display.do?method=detail&id=12727 Accessed: April 21, 2010
28. F. Cappuzzo, T. Ciuleanu, L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
29. B.H. Han, S.L. Ma, X.Q. Song Efficacy and symptom improvement data from a randomized, placebo-controlled, parallel-group study in patients from China with locally advanced or metastatic non-small-cell lung cancer (NSCLC) treated with gefitinib as maintenance therapy (INFORM) Oral presentation at the 14th Biennial World Conference on Lung Cancer; July 3-7 2011 Amsterdam, Netherlands, 2011 (abstract 831)
30. G. Metro, G. Finocchiaro, F. Cappuzzo Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance Ann Oncol 17 suppl 2 2006 ii42 ii45
31. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
32. M. Fukuoka, Y.L. Wu, S. Thongprasert Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 2011
33. C. Zhou, Y.L. Wu, G. Chen Erlotinib vs. chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 2011
34. R. Rosell, R. Gervais, A. Vergnenegre Erlotinib vs. chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial J Clin Oncol 29 2011 abstract 7503 www.asco.org Accessed: September 26, 2011
35. E.L. Kwak, R. Sordella, D.W. Bell Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib Proc Natl Acad Sci U S A 102 2005 7665 7670 (Pubitemid 40741028)
36. R. Perez-Soler, A. Chachoua, L.A. Hammond Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238 3247 (Pubitemid 41103678)
37. W. Pao Defining clinically relevant molecular subsets of lung cancer Cancer Chemother Pharmacol 58 suppl 1 2006 s11 s15
38. C.-H. Yang, M. Fukuoka, T.S. Mok Final overall survival (OS) results from a phase III, randomised, open-label, first-line study of gefitinib (G) V carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small cell lung cancer (NSCLC) in Asia (iPASS) Ann Oncol 21 2010 viii1 viii2 (abstract LBA2)
39. C.Q. Zhu, S.G. da Cunha, K. Ding Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 J Clin Oncol 26 2008 4268 4275
40. H. Greulich, T.H. Chen, W. Feng Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants PLoS Med 2 2005 e313
41. E. Massarelli, M. Varella-Garcia, X. Tang KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer Clin Cancer Res 13 2007 2890 2896 (Pubitemid 46849563)
42. W. Pao, T.Y. Wang, G.J. Riely KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 2005 e17
43. V.A. Miller, M. Zakowski, G.J. Riley EGFR mutation and copy number EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): results of a prospective phase II trial J Clin Oncol 24 2006 364s (abstract 7003)
44. R. Bianco, I. Shin, C.A. Ritter Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors Oncogene 22 2003 2812 2822 (Pubitemid 36609595)
45. J.M. Tang, Q.Y. He, R.X. Guo Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis Lung Cancer 51 2006 181 191
46. W.T. Lim, W.H. Zhang, C.R. Miller PTEN and phosphorylated Akt expression and prognosis in early- and late-stage non-small cell lung cancer Oncol Rep 17 2007 853 857
47. M.L. Sos, M. Koker, B.A. Weir PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR Cancer Res 69 2009 3256 3261
48. S. Thomson, E. Buck, F. Petti Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition Cancer Res 65 2005 9455 9462 (Pubitemid 41508014)
49. T.G. Bivona, H. Hieronymus, J. Parker FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR Nature 471 2011 523 526
50. W. Pao, V.A. Miller, K.A. Politi Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 2005 e73
51. S. Kobayashi, T.J. Boggon, T. Dayaram EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 2005 786 792 (Pubitemid 40271173)
52. T.A. Carter, L.M. Wodicka, N.P. Shah Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases Proc Natl Acad Sci U S A 102 2005 11011 11016 (Pubitemid 41105984)
53. J.A. Engelman, P.A. Janne Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer Clin Cancer Res 14 2008 2895 2899
54. A. Kumar, E.T. Petri, B. Halmos Structure and clinical relevance of the epidermal growth factor receptor in human cancer J Clin Oncol 26 2008 1742 1751
55. G.R. Oxnard, G.J. Riely, M.H. Arcila Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI) J Clin Oncol 28 2010 (abstract 7520) www.asco.org Accessed: September 26, 2011
56. C.H. Yun, K.E. Mengwasser, A.V. Toms The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc Natl Acad Sci U S A 105 2008 2070 2075 (Pubitemid 351439466)
57. S. Maheswaran, L.V. Sequist, S. Nagrath Detection of mutations in EGFR in circulating lung-cancer cells N Engl J Med 359 2008 366 377
58. R. Rosell, M.A. Molina, C. Costa Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies J Clin Oncol 28 2010 (abstract 7514) www.asco.org Accessed: September 26, 2011
59. M.N. Balak, Y. Gong, G.J. Riely Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors Clin Cancer Res 12 2006 6494 6501 (Pubitemid 44799723)
60. J. Bean, G.J. Riely, M. Balak Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma Clin Cancer Res 14 2008 7519 7525
61. J.C. Sok, F.M. Coppelli, S.M. Thomas Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting Clin Cancer Res 12 2006 5064 5073 (Pubitemid 44453332)
62. H. Ji, X. Zhao, Y. Yuza Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors Proc Natl Acad Sci U S A 103 2006 7817 7822
63. J.A. Engelman, K. Zejnullahu, T. Mitsudomi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043 (Pubitemid 46799492)
64. S. Yano, W. Wang, Q. Li Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations Cancer Res 68 2008 9479 9487
65. T. Yamada, K. Matsumoto, W. Wang Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer Clin Cancer Res 16 2010 174 183
66. F. Morgillo, W.Y. Kim, E.S. Kim Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib Clin Cancer Res 13 2007 2795 2803 (Pubitemid 46788049)
67. M.J. Fidler, S. Basu, L. Buckingham Insulin-like growth factor receptor 1 (IGFR-1) and outcome measures in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib J Clin Oncol 26 suppl 2008 abstract 8036 www.asco.org Accessed: September 26, 2011
68. N.B. Elkind, Z. Szentpetery, A. Apati Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib) Cancer Res 65 2005 1770 1777 (Pubitemid 40478603)
69. L.V. Sequist, B. Waltman, D. Dias-Santagata Small cell lung cancer harboring EGFR mutations: phenotype and genotype changes observed with acquired EGFR TKI resistance in EGFR-mutant NSCLC J Thorac Oncol 5 2010 S501 (abstract 2)
70. D.L. Wheeler, E.F. Dunn, P.M. Harari Understanding resistance to EGFR inhibitors-impact on future treatment strategies Nat Rev Clin Oncol 7 2010 493 507
71. D. Jackman, W. Pao, G.J. Riely Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer J Clin Oncol 28 2010 357 360
72. B.C. Cho, C.K. Im, M.S. Park Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib J Clin Oncol 25 2007 2528 2533
73. A. Horiike, N. Yamamoto, H. Tanaka Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer J Clin Oncol 28 suppl 2010 abstract 7573 www.asco.org Accessed: September 26, 2011
74. G.J. Riely, M.G. Kris, B. Zhao Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus Clin Cancer Res 13 2007 5150 5155 (Pubitemid 47502083)
75. S. Huang, E.A. Armstrong, S. Benavente Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor Cancer Res 64 2004 5355 5362 (Pubitemid 39006556)
76. Y.Y. Janjigian, C.G. Azzoli, L.M. Krug Phase I/II Trial of Cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib Clin Cancer Res 17 2011 2521 2527
77. D. Li, L. Ambrogio, T. Shimamura BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27 2008 4702 4711
78. N. Yamamoto, N. Katakami, S. Atagi A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib or gefitinib J Clin Oncol 29 suppl 2011 abstract 7524. Poster presented at: the Annual meeting of the American Society of Clinical Oncology; June 4-8, 2011; (abstract 7524)
79. Y.Y. Janjigian, H.J. Groen, L. Horn Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib J Clin Oncol 29 suppl 2011 abstract 7525 www.asco.org Accessed: September 26, 2011
80. K.L. Reckamp, K. Krysan, J.D. Morrow A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer Clin Cancer Res 12 2006 3381 3388
81. S.E. Witta, R.M. Gemmill, F.R. Hirsch Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines Cancer Res 66 2006 944 950 (Pubitemid 43165962)
82. R.M. Jotte, S.E. Witta, A.I. Spira Molecular analysis identifies a subset of non-small cell lung cancer patients with differential sensitivity to histone deacetylase inhibitor (HDACI)/epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment J Thorac Oncol 5 2010 S559 S560 (abstract LBOA3)
83. Y.N. Fu, C.L. Yeh, H.H. Cheng EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy Oncogene 27 2008 957 965 (Pubitemid 351225379)
84. E.B. Haura, T. Tanvetyanon, A. Chiappori Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer J Clin Oncol 28 2010 1387 1394
85. D. Ercan, K. Zejnullahu, K. Yonesaka Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor Oncogene 29 2010 2346 2356
86. C.D. Britten Targeting ErbB receptor signaling: a pan-ErbB approach to cancer Mol Cancer Ther 3 2004 1335 1342 (Pubitemid 39440177)
87. W. Zhou, D. Ercan, L. Chen Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 462 2009 1070 1074
88. C. Yang, J. Shih, W. Su A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-LUNG 2) Ann Oncol 21 2010 viii123 (abstract 367PD)
89. De Greve J, Decoster L, De Mey J, et al. Clinical activity of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2/neu. Paper presented at the 2nd European Lung Cancer Conference; April 28-May 1, 2010; Geneva, Switzerland.
90. V.A. Miller, V. Hirsh, J. Cadranel Subgroup analysis of LUX-Lung 1: a randomized phase III trial of afatinib (BIBW 2992) + best supportive care (BSC) vs. placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib J Thorac Oncol 5 2010 abstract LBPL3
91. S.K. Rabindran, C.M. Discafani, E.C. Rosfjord Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase Cancer Res 64 2004 3958 3965 (Pubitemid 38697310)
92. L.V. Sequist, B. Besse, T.J. Lynch Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer J Clin Oncol 28 2010 3076 3083
93. J.A. Engelman, K. Zejnullahu, C.M. Gale PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib Cancer Res 67 2007 11924 11932
94. P.A. Janne, J.H. Schellens, J.A. Engelman Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC J Clin Oncol 26 2008 8027
95. P.A. Janne, K. Reckamp, M. Koczywas A phase 2 trial of PF-00299804 (PF299), an oral irreversible HER tyrosine kinase inhibitor (TKI), in patients (pts) with advanced NSCLC after failure of prior chemotherapy and erlotinib: preliminary efficacy and safety results J Thorac Oncol 4 2009 S293 S294 (abstract A3.1)
96. A. Campbell, K.L. Reckamp, D.R. Camidge PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): a phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E) J Clin Oncol 28 2010 7596
97. Park K, Heo DS, Cho BC, et al. PF299804 in Asian patients with non-small cell lung cancer refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): a phase (P) I/II study. Oral presentation at: the 46th Annual Meeting at the American Society of Clinical Oncology; June 4-8, 2010; Chicago, IL, USA.
98. Boyer MJ, Blackhall FH, Park K, et al. Efficacy and safety of PF299804 versus erlotinib: a global, randomized phase 2 trial in patients with advanced non-small cell lung cancer after failure of chemotherapy. Oral presentation at: the 46th Annual Meeting at the American Society of Clinical Oncology; June 4-8, 2010; Chicago, IL, USA.
99. T. Mok, D.R. Spigel, K. Park Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC) J Clin Oncol 28 2010 7537
100. R. Bahleda, J.C. Soria, C.T. Harbison Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514 J Clin Oncol 27 2009 431s (abstract 8098)
101. V.A. Miller, H.A. Wakelee, P.N. Lara Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: preliminary results of a phase II trial J Clin Oncol 26 2008 8028
102. J. Chmielecki, M.C. Pietanza, M. Kris Selective pressure for the EGFR T790M resistance mutation may be different for different EGFR tyrosine kinase inhibitors J Thorac Oncol 5 2010 S250 (abstract B29)
103. J. Bean, C. Brennan, J.Y. Shih MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc Natl Acad Sci U S A 104 2007 20932 20937
104. E.L. Kwak, Y.J. Bang, D.R. Camidge Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
105. L.V. Sequist, J. von Pawel, E.G. Garmey Randomized phase II study of erlotinib plus tivantinib vs. erlotinib plus placebo in previously treated non-small-cell lung cancer J Clin Oncol 29 2011 3307 3315
106. D.R. Spigel, T.J. Ervin, R. Ramlau Randomized global double-blind phase II study evaluating MetMAb in combination with erlotinib, in patients with advanced non-small cell lung cancer J Thorac Oncol 5 2010 S557 (abstract LBPL1)
107. H.A. Wakelee, S.N. Gettinger, J.A. Engelman A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC) J Clin Oncol 28 suppl 2010 15 (abstract 3017)
108. R. Sangha, P.N. Lara Jr, P.C. Mack, D.R. Gandara Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier Curr Opin Oncol 21 2009 116 123
109. D.D. Karp, L.G. Paz-Ares, S. Novello Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer J Clin Oncol 27 2009 2516 2522
110. A. Gualberto, M. Pollak Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions Oncogene 28 2009 3009 3021
111. J. Jassem, C.J. Langer, D.D. Karp Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin vs. paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) J Clin Oncol 28 2010 7500
112. T. Shimamura, A.M. Lowell, J.A. Engelman Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins Cancer Res 65 2005 6401 6408 (Pubitemid 40994428)
113. D. Li, T. Shimamura, H. Ji Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy Cancer Cell 12 2007 81 93 (Pubitemid 47001787)
114. N.B. Leighl, J. Soria, J. Bennouna Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC) J Clin Oncol 28 2010 7524
115. K.A. Price, C.G. Azzoli, L.M. Krug Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer J Thorac Oncol 5 2010 1623 1629
116. J. Dimitroulakos, I.A. Lorimer, G. Goss Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway Clin Cancer Res 12 2006 4426s 4431s (Pubitemid 44197193)
117. T.T. Zhao, B.G. Le Francois, G. Goss Lovastatin inhibits EGFR dimerization and Akt activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins Oncogene 29 2010 4682 4692
118. C. Cemeus, T.T. Zhao, G.M. Barrett Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status J Neurooncol 90 2008 9 17
119. D.B. Costa, S.T. Schumer, D.G. Tenen Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations J Clin Oncol 26 2008 1182 1184